Ranitidine recall – Sanofi

30 de octubre del 2019

On October 22, 2019, Sanofi issued a voluntary recall of Zantac OTC (over-the-counter) products due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will mail letters to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

Zantac OTC (over-the-counter) Products:

Zantac 150®

Zantac 150® Cool Mint

Zantac 75®

Additional information is available on the FDA's website:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us

Última actualización: 13 de marzo del 2020